Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
143.41(c) 145.49(c) 143.38(c) 144.9(c) 144.75(c) Last
4 626 099 5 064 305 3 794 513 4 127 874 3 223 766 Volume
+2.31% +1.45% -1.45% +1.06% -0.10% Change
More quotes
Financials (USD)
Sales 2020 23 681 M - -
Net income 2020 6 011 M - -
Net Debt 2020 11 184 M - -
P/E ratio 2020 23,2x
Yield 2020 2,00%
Sales 2021 25 979 M - -
Net income 2021 7 174 M - -
Net Debt 2021 8 770 M - -
P/E ratio 2021 18,9x
Yield 2021 2,20%
Capitalization 134 B 134 B -
EV / Sales 2020 6,12x
EV / Sales 2021 5,49x
Nbr of Employees 33 625
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both... 
Sector
Pharmaceuticals
Calendar
12/15 | 09:00amGuidance Call
More about the company
Notations Surperformance© of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
All news about ELI LILLY AND COMPANY
11/25ELI LILLY AND COMPANY : - Lilly to Participate in Evercore ISI 3rd Annual Health..
AQ
11/24ELI LILLY AND : Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Confe..
PR
11/24ELI LILLY AND : to Supply Bamlanivimab to Treat Covid-19 in Canada
DJ
11/24UPS Preparing to Help Ship, Store Covid-19 Vaccines
DJ
11/23REGENERON PHARMACEUTICALS : U.S. to begin distributing Regeneron's COVID-19 anti..
RE
11/23ELI LILLY AND COMPANY : - Lilly and Precision BioSciences Announce Genome Editin..
AQ
11/23ELI LILLY AND COMPANY : - Lilly's neutralizing antibody bamlanivimab receives in..
AQ
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
DJ
11/21REGENERON PHARMACEUTICALS : FDA Authorizes Regeneron's Covid-19 Antibody Cocktai..
DJ
11/20ELI LILLY AND : Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives ..
AQ
11/20ELI LILLY AND : Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives ..
PR
11/20ELI LILLY AND COMPANY : - Baricitinib Receives Emergency Use Authorization from ..
AQ
11/20ELI LILLY AND COMPANY : - Lilly and Ypsomed collaborate to advance an automated ..
AQ
11/19ELI LILLY AND : Incyte Say FDA Grants EUA for Baricitinib
DJ
11/19GILEAD SCIENCES : Eli Lilly arthritis drug gets FDA nod for emergency use with r..
RE
More news
News in other languages on ELI LILLY AND COMPANY
11/22COVID-19 : les Etats-Unis espèrent commencer à vacciner à la mi-décembre
11/21COVID-19 : le traitement de Regeneron approuvé, 12 millions de cas aux Etats-Uni..
11/20ELI LILLY : signe un accord avec Precision BioSciences
11/19Ypsomed confie à Eli Lilly la distribution future de l'Ypsopump aux Etats-Uni..
11/10ELI LILLY : la FDA autorise une thérapie pour des anticorps
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 164,58 $
Last Close Price 147,64 $
Spread / Highest target 35,5%
Spread / Average Target 11,5%
Spread / Lowest Target -18,7%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY10.13%131 228
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555